Aligos Therapeutics to Present Novel HBV Therapy at The Liver Meeting® 2025
Aligos Therapeutics, a biotech firm specialising in liver and viral diseases, is set to make waves at The Liver Meeting® 2025. The company, listed on the Nasdaq as ALGS, will present eight studies, including an oral presentation on a novel therapy for chronic hepatitis B virus (HBV) infection.
ALG-000184, the star of the presentation, is a capsid assembly modulator. It directly targets and suppresses hepatitis B DNA, even in patients who haven't received treatment before. In clinical trials, it has shown sustained reduction of hepatitis B antigen levels over 96 weeks. The therapy also prevents the formation of cccDNA, a form of hepatitis B DNA that can integrate into the host's genome, and blocks hepatitis B DNA integration in vitro. Another capsid assembly modulator, ALG-001075, specifically targets HBeAg, a protein produced during hepatitis B infection.
Aligos Therapeutics' pipeline is broad, covering not only hepatitis B but also metabolic dysfunction-associated steatohepatitis (MASH) and coronaviruses. The company's researchers, though not publicly named, are at the forefront of these innovations. The Liver Meeting® 2025, held in Washington, D.C. from November 7 to 11, 2025, will be the stage for these groundbreaking presentations.
Aligos Therapeutics' eight presentations at The Liver Meeting® 2025 highlight the company's commitment to improving patient outcomes for liver and viral diseases. The oral presentation on ALG-000184, a promising therapy for chronic hepatitis B infection, is particularly noteworthy. With a pipeline spanning hepatitis B, MASH, and coronaviruses, Aligos Therapeutics is making significant strides in biotechnology.
Read also:
- Prehistoric Stone Artifacts Discovered, Unconnected to Any Recognized Early Human Species!
- Old Kilo finally retired after 130 years:Justifying the introduction of a new standard kilogram and commencing a new measurement phase.
- Advancing Cancer Research through Computer Vision Techniques
- Leuna facility to receive millions for green hydrogen production
